Alcaftadine 0.25% Versus Olopatadine 0.2% In Prevention Of Ocular Itching In Allergic Conjunctivitis

被引：2
|
作者：
McLaurin, Eugene B. [1 ]
Marsico, Nicholas P. [2 ]
Ciolino, Joseph B. [3 ]
Villanueva, Linda [4 ]
Williams, Julia M. [4 ]
Hollander, David A. [4 ]
机构：
[1] Total Eye Care PA, Memphis, TN USA
[2] East West Eye Inst, Los Angeles, CA USA
[3] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA
[4] Allergan Pharmaceut Inc, Irvine, CA 92715 USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2014年 / 133卷 / 02期
关键词：
D O I：
10.1016/j.jaci.2013.12.986
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
961
引用
收藏
页码：AB278 / AB278
页数：1
相关论文
共 50 条
  • [1] ALCAFTADINE 0.25% VERSUS OLOPATADINE 0.2% IN THE PREVENTION OF OCULAR ITCHING IN ALLERGIC CONJUNCTIVITIS
    McLaurin, E. B.
    Marsico, N. P.
    Ciolino, J. B.
    Williams, J. M.
    Hollander, D. A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2013, 111 (05) : A19 - A19
  • [2] Ocular Itch Relief with Alcaftadine 0.25% Versus Olopatadine 0.2% in Allergic Conjunctivitis: Pooled Analysis of Two Multicenter Randomized Clinical Trials
    McLaurin, Eugene B.
    Marsico, Nicholas P.
    Ackerman, Stacey L.
    Ciolino, Joseph B.
    Williams, Julia M.
    Villanueva, Linda
    Hollander, David A.
    ADVANCES IN THERAPY, 2014, 31 (10) : 1059 - 1071
  • [3] Ocular Itch Relief with Alcaftadine 0.25% Versus Olopatadine 0.2% in Allergic Conjunctivitis: Pooled Analysis of Two Multicenter Randomized Clinical Trials
    Eugene B. McLaurin
    Nicholas P. Marsico
    Stacey L. Ackerman
    Joseph B. Ciolino
    Julia M. Williams
    Linda Villanueva
    David A. Hollander
    Advances in Therapy, 2014, 31 : 1059 - 1071
  • [4] Alcaftadine for the Prevention of Itching Associated with Allergic Conjunctivitis
    Mahvan, Tracy D.
    Buckley, Whitney A.
    Hornecker, Jaime R.
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (7-8) : 1025 - 1032
  • [5] The safety and efficacy of alcaftadine 0.25% ophthalmic solution for the prevention of itching associated with allergic conjunctivitis
    Torkildsen, Gail
    Shedden, Arthur
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (03) : 623 - 631
  • [6] Alcaftadine 0.25% versus Olopatadine 0.1% in Preventing Cedar Pollen Allergic Conjunctivitis in Japan: A Randomized Study
    Nakatani, Hiroshi
    Gomes, Paul
    Bradford, Ron
    Guo, Qiang
    Safyan, Eleonora
    Hollander, David A.
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2019, 27 (04) : 622 - 631
  • [7] Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis
    Ayyappanavar, Shruti
    Sridhar, Sriya
    Kumar, Kiran
    Jayanthi, C. R.
    Gangasagara, Suresh Babu
    Rathod, B. L. Sujatha
    Preethi, B.
    Mittal, Preeti
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2021, 69 (02) : 257 - 261
  • [8] Comparative assessment of alcaftadine and olopatadine for allergic conjunctivitis: a meta-analysis
    Fu, Xiaojuan
    Xu, Peijie
    Lu, Di
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2024, 41 (06): : 560 - 565
  • [9] Comparison of alcaftadine with olopatadine for allergic conjunctivitis: A meta-analysis study
    Xuan, J.
    Tan, X.
    Liu, H.
    Liu, T.
    REVUE FRANCAISE D ALLERGOLOGIE, 2023, 63 (06):
  • [10] Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%
    Greiner, Jack V.
    Edwards-Swanson, Kimberly
    Ingerman, Avner
    CLINICAL OPHTHALMOLOGY, 2011, 5 : 87 - 93
12345